Cite
MLA Citation
Johanna C. Bendell et al.. “A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma.” Cancer, vol. 121, no. 19, 2015, pp. 3481–3490. http://access.bl.uk/ark:/81055/vdc_100026472413.0x000014